The 41% Growth That Almost Didn't Happen

INTCO Medical, the world's largest non-latex disposable glove maker, reported first-half 2026 revenue of 6.9 billion yuan — a 41% jump from the same period last year. Net income rose to 837 million yuan from 710 million. Earnings per share climbed to 1.31 yuan from 1.12.

On the surface, this reads like a company reaccelerating after a two-year post-pandemic slowdown. But the headline hides a more dramatic — and more revealing — story inside the quarter-by-quarter breakdown.

In the first quarter of 2026, INTCO's net profit collapsed by 97% year over year, from 352 million yuan to just 10 million. The Q1 profit wasn't down because demand dried up — it evaporated because of industry-wide margin compression and inventory write-downs that plagued the entire glove sector after years of oversupply.

Then Q2 hit. With Q1 accounting for only 10 million yuan of the 837 million yuan first-half total, the second quarter alone produced roughly 827 million yuan in net profit. That's more than double what Q1 2025 generated. The company didn't just recover — it swung from near-breakeven to the kind of profitability that makes the full-half number look like a turnaround.

Why does this quarter swing matter? Because it tells you exactly what's happening to nitrile glove prices, and whether INTCO's massive capacity expansion is starting to pay off or running into the same trap that hurt every other manufacturer.

The glove cycle: from pandemic panic to price war to normalization

To understand INTCO, you have to understand the glove industry's wild ride. During the pandemic, nitrile glove prices surged several-fold as hospitals and factories worldwide raced to stockpile. Every manufacturer built capacity fast — and then kept building after demand normalized. By 2024 and 2025, the market was flooded. Prices crashed. Inventory write-downs gutted profits across the sector. Even Top Glove, the Malaysian giant that was the poster child for pandemic-era investing, posted structural losses for three years.

INTCO was no exception. That Q1 2026 profit collapse wasn't an operational failure. It was the tail end of the oversupply hangover — inventory adjustments and compressed margins catching up to a business that had to clear through the worst of the cycle.

But starting in mid-2025 and accelerating into 2026, the dynamic shifted. Nitrile glove prices began climbing again, driven by tightening supply chains, geopolitical instability disrupting shipping routes, rising raw material costs, and the gradual shakeout of weaker producers who couldn't survive the price war. Industry suppliers noted that average selling prices were recovering, and the companies with the deepest balance sheets and largest scale were the ones positioned to benefit.

INTCO's H1 2026 results capture that transition perfectly. The Q1 disaster reflects the last gasp of the downturn. The Q2 explosion reflects prices moving back in the manufacturer's favor.

Capacity as conviction — and leverage

Here's where the story gets interesting. While competitors were struggling through the downturn, INTCO kept expanding.

As of the end of 2025, the company's annualized production capacity reached 103 billion pieces — 70 billion nitrile and 33 billion vinyl. That made it the world's largest non-latex glove manufacturer by capacity. The company operates 10 production bases across China and overseas, including new facilities in Vietnam designed to strengthen supply chain resilience and reduce exposure to U.S. tariffs on Chinese-made medical devices.

The product yield sits above 99%, which matters in a thin-margin commodity business. A 1 percentage point of waste is 1 percentage point off the bottom line.

But expansion comes with a price — literally. INTCO's balance sheet has transformed from the virtually debt-free position of a few years ago into something that demands scrutiny. Total debt has climbed from 292 million yuan in 2021 to roughly 17.5 billion yuan by mid-2026. Against shareholder equity of 18.6 billion yuan, that gives the company a debt-to-equity ratio of about 95%.

Cash and investments sit at 15.1 billion yuan as of June 2026, which keeps net debt manageable at around 2.3 billion yuan. Still, the trend is clear: this is a company that has financed aggressive growth with borrowings, and those borrowings require the revenue and margin expansion to actually materialize.

The capital intensity shows in the cash flow numbers. Trailing-twelve-month capital expenditures totaled about 1.9 billion yuan against 2.9 billion yuan in operating cash flow — leaving free cash flow of roughly 989 million yuan. That's positive, but it's also the first sustained positive free cash flow period after years of negative FCF during the heavy investment phase. The 2025 full year showed negative free cash flow of nearly 690 million yuan, and 2023 was worse at nearly 940 million in negative free cash flow.

The point isn't that the balance sheet is broken. It's that INTCO has taken on significant financial leverage to fund capacity expansion in a commodity market. That works beautifully when prices recover and capacity utilization is high — which is exactly what the H1 2026 numbers suggest is happening. But it creates real downside risk if the glove cycle turns back the other way.

The pricing power question

The central test for any business in a cyclical commodity market is pricing power — the ability to raise prices without losing customers. For nitrile gloves, the answer is partial. Healthcare and industrial demand for gloves is structural and growing — the global nitrile gloves market is estimated at roughly 6.9 billion dollars in 2026 and projected to grow at a 7-10% CAGR through the decade. But the product is largely undifferentiated. A hospital in Ohio doesn't need INTCO gloves specifically — it needs gloves that meet regulatory standards at the best price.

INTCO's edge isn't brand power. It's cost leadership through scale. Being the largest manufacturer with 103 billion pieces of capacity, near-99% yield rates, and vertically integrated operations across China and Vietnam gives the company the lowest-cost structure in the industry. In a commodity market, the low-cost producer is the one that stays profitable when prices fall and captures the most margin when they rise.

That's a moat — just not the kind that lets you charge a premium.

What the valuation says

INTCO trades on the Shenzhen Stock Exchange (300677.SZ) at a market capitalization of roughly 32 billion yuan, or about $5.4 billion. The trailing P/E ratio sits around 17-18x based on the current H1 run rate, but the forward P/E comes in closer to 11x. That's less than half the industry average of 22x.

The dividend yield is minimal at roughly 0.35%. This isn't an income stock — it's a cyclical growth story disguised as a healthcare name.

The valuation gap between trailing and forward multiples is telling. Analysts expect earnings to nearly double as the glove price recovery continues through the second half of 2026. If that materializes, the 11x forward multiple would compress to something lower. If it doesn't — if the cycle peaks sooner than expected or tariffs disrupt the business — that 17x trailing multiple looks expensive for a leveraged commodity producer.

The risk the headline doesn't show

U.S. tariffs on Chinese medical devices add another layer of uncertainty. INTCO's Vietnam operations are partly designed to mitigate this risk, but tariff exposure remains a material headwind for a company whose products flow heavily into North America. The company also diversifies into rehabilitation equipment — wheelchairs and physical therapy devices — which grew during 2025 and provides a partial hedge against glove cyclicality. Still, gloves dominate the revenue mix.

The bigger risk is the cycle itself. Glove prices rose in 2026 after a brutal multi-year downturn. But commodity markets cycle. The same capacity expansion that gives INTCO a cost advantage also adds to global supply. If new capacity from INTCO and other expanding producers overwhelms demand growth, prices will soften again — and a company with 17.5 billion yuan of debt has less cushion to absorb it.

Where this leaves the investment case

INTCO Medical's H1 2026 results tell a clear story: a company that rode through one of the worst parts of a commodity cycle just as prices began to turn. The Q1-to-Q2 swing is the single most informative data point — it shows that the underlying economics are improving, not deteriorating. Revenue grew 41% and profitability more than doubled versus the prior year, suggesting the nitrile price recovery is real and INTCO's scale advantage is translating into earnings.

The question isn't whether the turnaround is happening. It's whether the balance sheet can withstand another downturn if one comes, and whether the capacity expansion that made INTCO the world's largest also puts it at risk of recreating the oversupply that caused the last crisis.

This is a cyclical business in a real-economy sector with structural demand growth — hygiene standards aren't going back to pre-pandemic levels. But it's not a compounder in the traditional sense. It's a leveraged bet that the glove cycle has bottomed and that INTCO's cost leadership is durable enough to turn scale into earnings power.

If you believe nitrile glove prices have found a new floor and that the global demand growth of 7-10% per year can absorb the expanding capacity, INTCO's forward valuation at roughly 11x earnings makes the risk-reward favorable. If you believe the capacity build will eventually crush margins again — as it did in 2024-2025 — the leverage works against you.

The data you need to watch is simple: nitrile glove average selling prices, utilization rates at INTCO's newest facilities, and whether that positive free cash flow trend sustains through the next earnings report. The Q2 recovery was dramatic. The question is whether it's the start of a new expansion phase or just a bounce before the cycle turns again.